1-phenyl-2-palmitoylamino-3-morpholino-1-propanol has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 1 studies
1-phenyl-2-palmitoylamino-3-morpholino-1-propanol: a sphingolipid analog; inhibits the enzyme activity in infected erythrocytes
N-[1-hydroxy-3-(morpholin-4-yl)-1-phenylpropan-2-yl]hexadecanamide : A fatty amide resulting from the formal condensation of palmitic acid with the primary amino group of 2-amino-3-(morpholin-4-yl)-1-phenylpropan-1-ol.
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Donnell, PH | 1 |
| Guo, WX | 1 |
| Reynolds, CP | 1 |
| Maurer, BJ | 1 |
1 other study available for 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.
Topics: Antineoplastic Agents; Cell Survival; Ceramides; Dose-Response Relationship, Drug; Drug Synergism; F | 2002 |